Literature DB >> 9435159

Mechanism of hypocholesterolemic action of S-8921 in rats: S-8921 inhibits ileal bile acid absorption.

T Ichihashi1, M Izawa, K Miyata, T Mizui, K Hirano, Y Takagishi.   

Abstract

The mechanism of the hypocholesterolemic action of S-8921, methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)- 4-hydroxy-6,7,8-trimethoxy-2-naphthoate, was examined in rats. In diet-induced hypercholesterolemic rats, 2 weeks oral administration of S-8921 dose- and time-dependently decreased plasma cholesterol level in the daily dose range of 0.1 to 10 mg/kg. Results with the dual-isotope plasma ratio method indicated that S-8921 inhibits cholesterol absorption from the intestine and enhances its elimination from the body. The in situ loop method showed that S-8921 does not inhibit the absorption of cholesterol from rat jejunum, clearly inhibits active absorption of taurocholic acid (TCA) and glycocholic acid (GCA) from rat ileum and does not inhibit passive absorption of cholic acid (CA) from the rat jejunum. In rat ileal brush-border membrane vesicles, S-8921 inhibited the sodium-dependent uptake of TCA in a concentration-dependent manner with IC50 of 2.1 microM, not the Na(+)-dependent D-glucose and L-alanine uptake. These results suggest that S-8921 is a potent, selective inhibitor of the Na(+)-dependent bile acid transport system in the ileal mucosal cell brush-border membrane, and this inhibition is the mechanism by which this drug decreases intestinal bile acid reabsorption to result in a significant decrease of plasma cholesterol.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9435159

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  LDL-C-lowering therapy: current and future therapeutic targets.

Authors:  Maartje E Visser; Lily Jakulj; John J P Kastelein; Erik S G Stroes
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

2.  Studies on antidyslipidemic effects of Morinda citrifolia (Noni) fruit, leaves and root extracts.

Authors:  Saf-ur Rehman Mandukhail; Nauman Aziz; Anwarul-Hassan Gilani
Journal:  Lipids Health Dis       Date:  2010-08-20       Impact factor: 3.876

Review 3.  The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships.

Authors:  J Geyer; T Wilke; E Petzinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-16       Impact factor: 3.000

4.  Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter.

Authors:  Xiaowan Zheng; Sean Ekins; Jean-Pierre Raufman; James E Polli
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

5.  Studies on the antihypertensive and antidyslipidemic activities of Viola odorata leaves extract.

Authors:  Hasan S Siddiqi; Malik H Mehmood; Najeeb U Rehman; Anwar H Gilani
Journal:  Lipids Health Dis       Date:  2012-01-10       Impact factor: 3.876

6.  In Vivo Antihypercholesterolemic Potential of Swietenia mahagoni Leaf Extract.

Authors:  Naveen Yelaware Puttaswamy; Asna Urooj
Journal:  Cholesterol       Date:  2016-10-13

Review 7.  Pharmacological Properties and Health Benefits of Eugenol: A Comprehensive Review.

Authors:  Muhammad Farrukh Nisar; Mahnoor Khadim; Muhammad Rafiq; Jinyin Chen; Yali Yang; Chunpeng Craig Wan
Journal:  Oxid Med Cell Longev       Date:  2021-08-03       Impact factor: 6.543

8.  Antihypercholesterolemic and Antioxidative Potential of an Extract of the Plant, Piper betle, and Its Active Constituent, Eugenol, in Triton WR-1339-Induced Hypercholesterolemia in Experimental Rats.

Authors:  Karuppasamy Venkadeswaran; Arumugam Ramachandran Muralidharan; Thangaraj Annadurai; Vasanthakumar Vasantha Ruban; Mahalingam Sundararajan; Ramalingam Anandhi; Philip A Thomas; Pitchairaj Geraldine
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-09       Impact factor: 2.629

9.  Studies on two polyherbal formulations (ZPTO and ZTO) for comparison of their antidyslipidemic, antihypertensive and endothelial modulating activities.

Authors:  Nauman Aziz; Malik Hassan Mehmood; Anwarul-Hassan Gilani
Journal:  BMC Complement Altern Med       Date:  2013-12-26       Impact factor: 3.659

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.